Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections

Article Immunology

Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections

Pranita D. Tamma et al.

Summary: The Infectious Diseases Society of America (IDSA) has provided updated guidance on the treatment of antimicrobial-resistant infections, focusing on treating AmpC-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. The guidance is based on clinical experience, expert opinion, and a review of available literature, as published data on optimal treatment options are limited. This document emphasizes treatment approaches for infections in the United States, considering differences in resistance epidemiology and the availability of specific anti-infectives internationally.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Microbiology

Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii

Marco Falcone et al.

Summary: Cefiderocol appears to be a promising therapeutic option for carbapenem-resistant Acinetobacter baumannii (CRAB) infections, with a potential protective effect on 30-day mortality. However, further studies are needed to address the issue of microbiological failure.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

添加到收藏夹

Article Immunology

Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients

Marco Falcone et al.

Summary: In this study, cefiderocol was used to treat patients with bacteremia or ventilator-associated pneumonia caused by drug-resistant strains, showing a 70% clinical success rate and 90% survival rate. However, two patients experienced microbiological failure, highlighting the need for future prospective studies to further evaluate the effectiveness of the treatment.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Matteo Bassetti et al.

Summary: The study assessed the efficacy and safety of cefiderocol versus best available therapy in the treatment of patients with carbapenem-resistant Gram-negative infections. Cefiderocol showed similar clinical and microbiological efficacy to best available therapy in this heterogeneous patient population with infections caused by carbapenem-resistant Gram-negative bacteria, suggesting it as an option for the treatment of carbapenem-resistant infections in patients with limited treatment options.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

Richard G. Wunderink et al.

Summary: Cefiderocol was found to be non-inferior to high-dose, extended-infusion meropenem in terms of all-cause mortality on day 14 in patients with Gram-negative nosocomial pneumonia, with similar tolerability. This suggests that cefiderocol is a potential option for the treatment of patients with nosocomial pneumonia, including those caused by multidrug-resistant Gram-negative bacteria.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Cefiderocol-Based Combination Therapy for Difficult-to-Treat Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives

Davide Fiore Bavaro et al.

Summary: This study investigated the efficacy of cefiderocol-based combination therapies as rescue treatments for eradicating severe infections caused by multidrug-resistant bacteria. Most patients were immunocompromised or critically ill, and showed good treatment outcomes during the course of therapy, with some deaths attributed to other causes.

ANTIBIOTICS-BASEL (2021)

添加到收藏夹

Article Infectious Diseases

Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections

Marianna Meschiari et al.

Summary: This study describes the real-life experience of using cefiderocol in XDR and difficult-to-treat resistant Pseudomonas aeruginosa infections without other treatment options available. Clinical cure and microbiological cure rates were 70.6% and 76.5% respectively, with a mortality rate of 35.3%.

JAC-ANTIMICROBIAL RESISTANCE (2021)

添加到收藏夹

Article Infectious Diseases

Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study

Renato Pascale et al.

Summary: This study confirms the potential role of cefiderocol in the treatment of CR-Ab infection, but larger clinical studies are needed for further validation.

JAC-ANTIMICROBIAL RESISTANCE (2021)

添加到收藏夹

Article Infectious Diseases

Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study

Renato Pascale et al.

Summary: This study analyzed the impact of cefiderocol use on patients with severe COVID-19 admitted to the ICU and further diagnosed with carbapenem-resistant Acinetobacter baumannii (CR-Ab) infection. The results suggest that cefiderocol may have a potential role in the treatment of CR-Ab infection, but larger clinical studies are needed for confirmation.

JAC-ANTIMICROBIAL RESISTANCE (2021)

添加到收藏夹

Article Immunology